NexImmune (NEXI) Competitors $0.0001 0.00 (0.00%) As of 09:39 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock NEXI vs. ATNFW, LBPSW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, CELUW, and CINGWShould you be buying NexImmune stock or one of its competitors? The main competitors of NexImmune include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), Celularity (CELUW), and Cingulate (CINGW). These companies are all part of the "pharmaceutical products" industry. NexImmune vs. Its Competitors 180 Life Sciences 4D pharma Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Celularity Cingulate 180 Life Sciences (NASDAQ:ATNFW) and NexImmune (NASDAQ:NEXI) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation. Does the media favor ATNFW or NEXI? In the previous week, 180 Life Sciences had 1 more articles in the media than NexImmune. MarketBeat recorded 1 mentions for 180 Life Sciences and 0 mentions for NexImmune. 180 Life Sciences' average media sentiment score of 0.00 equaled NexImmune'saverage media sentiment score. Company Overall Sentiment 180 Life Sciences Neutral NexImmune Neutral Which has stronger earnings and valuation, ATNFW or NEXI? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/ANexImmuneN/AN/A-$32.34M-$18.540.00 Do institutionals and insiders hold more shares of ATNFW or NEXI? 9.9% of NexImmune shares are held by institutional investors. 14.9% of NexImmune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is ATNFW or NEXI more profitable? 180 Life Sciences' return on equity of 0.00% beat NexImmune's return on equity.Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A NexImmune N/A -534.32%-213.72% Summary180 Life Sciences beats NexImmune on 3 of the 5 factors compared between the two stocks. Get NexImmune News Delivered to You Automatically Sign up to receive the latest news and ratings for NEXI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEXI vs. The Competition Export to ExcelMetricNexImmunePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$1.03B$6.22B$10.54BDividend YieldN/A4.84%5.74%4.88%P/E Ratio0.001.2829.1327.15Price / SalesN/A31.55554.35164.78Price / CashN/A17.6337.3861.65Price / Book0.007.7812.306.46Net Income-$32.34M-$8.09M$3.33B$276.63M7 Day PerformanceN/A2.04%-1.46%-2.62%1 Month PerformanceN/A26.01%5.03%0.29%1 Year PerformanceN/A-14.40%61.45%30.61% NexImmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEXINexImmuneN/A$0.00flatN/A-100.0%$0.00N/A0.0070ATNFW180 Life SciencesN/A$0.06+0.7%N/A+325.7%$0.00N/A0.007LBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAIMDWAinosN/A$0.16-25.2%N/A+246.3%$0.00$110.87K0.0040Positive NewsGap UpALVOWAlvotechN/A$1.60+6.7%N/A-39.6%$0.00$560.10M0.004Positive NewsGap UpACABWAtlantic Coastal Acquisition Corp. IIN/A$0.03+12.9%N/A-29.8%$0.00N/A0.0015Gap UpBFRIWBiofronteraN/A$0.10+2.9%N/A+364.6%$0.00$39.19M0.0070Positive NewsBTMDWbioteN/A$0.01-15.8%N/A-97.7%$0.00$199.07M0.00N/AGap DownHigh Trading VolumeBCTXWBriaCell TherapeuticsN/A$0.06-0.2%N/A-79.9%$0.00N/A0.008CELUWCelularityN/A$0.03-10.0%N/A+84.0%$0.00$44.59M0.00220Positive NewsShort Interest ↓CINGWCingulateN/A$0.04-38.4%N/A-21.1%$0.00N/A0.0020Positive NewsGap Up Related Companies and Tools Related Companies 180 Life Sciences Competitors 4D pharma Competitors Ainos Competitors Alvotech Competitors Atlantic Coastal Acquisition Corp. II Competitors Biofrontera Competitors biote Competitors BriaCell Therapeutics Competitors Celularity Competitors Cingulate Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NEXI) was last updated on 10/22/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryCurious about crypto but still stuck scrolling endless threads? People who get in early aren’t just lucky—they...Crypto 101 Media | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredA Worldwide Gold Lockdown Is Now UnderwayCentral banks around the world are hoarding gold at one of the fastest rates in history — and former Goldman S...Stansberry Research | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredTrump cannot stop this trainThe Nobel Committee just confirmed what free-market thinkers have long argued — that true wealth isn’t built t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NexImmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NexImmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NEXI Stock Alerts